CIA
ALDX icon

Caerus Investment Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Caerus Investment Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,455
Closed -$19.4K – 341
2026
Q1 		$19.4K Buy
+11,455
New +$50.2K 0.01% 274

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Caerus Investment Advisors's ALDX Position: Q2 2026 in Review

Caerus Investment Advisors sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 11,455 shares — an estimated $19.4K sold.

Caerus Investment Advisors first reported a position in ALDX in Q1 2026 and held it in 1 quarter. The position peaked at $19.4K in Q1 2026. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Caerus Investment Advisors reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caerus Investment Advisors sold 11,455 Aldeyra Therapeutics shares in Q2 2026, an estimated $19.4K.
  • Caerus Investment Advisors first reported a position in Aldeyra Therapeutics in Q1 2026 and held it in 1 quarter.
  • Caerus Investment Advisors's Aldeyra Therapeutics position peaked at $19.4K in Q1 2026.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Caerus Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.